Form 4: Immunovant CLO Sells Shares for Tax Obligations

Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 10,813 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Christopher Van Tuyl, Chief Legal Officer of Immunovant, Inc. (IMVT), reported the sale of 10,813 shares of common stock.
• The transactions occurred on December 18, 2025, and were executed under a Rule 10b5-1 pre-arranged trading plan.
• The sales were specifically to cover tax withholding obligations associated with the vesting and settlement of 27,489 restricted stock units (RSUs) that vested on December 16, 2025.
• The RSUs were part of a larger grant of 109,956 RSUs initially reported on December 18, 2024.
• The shares were sold in two batches: 8,529 shares at a weighted average price of $26.78 (ranging from $26.23 to $27.22) and 2,284 shares at a weighted average price of $27.38 (ranging from $27.25 to $27.52).
• Following these transactions, Christopher Van Tuyl beneficially owns 149,930 shares of Immunovant common stock.
• The sale was mandated by the Issuer's policy to require tax withholding obligations to be funded by a 'sell to cover' transaction and was not a discretionary sale by the reporting person.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is a common practice for executives receiving equity compensation. It does not reflect a change in the executive's or company's outlook.

Positives

• The vesting of 27,489 restricted stock units (RSUs) on December 16, 2025, represents a positive compensation event for the Chief Legal Officer.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing details a routine 'sell to cover' transaction by an executive, which is a common practice across industries for managing tax liabilities arising from equity compensation. It does not indicate any specific industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary transaction for tax purposes and is unlikely to have a significant impact on shareholder perception or the company's stock price.
• Employees: The transaction reflects standard equity compensation practices for executives, which is common across publicly traded companies.

Key Dates

Keywords

Immunovant, IMVT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Rule 10b5-1, Executive Compensation